Northwestern Mutual Investment Management Company LLC decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 81.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,095 shares of the medical instruments supplier’s stock after selling 34,926 shares during the quarter. Northwestern Mutual Investment Management Company LLC’s holdings in Becton, Dickinson and were worth $1,373,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. Janney Montgomery Scott LLC increased its position in Becton, Dickinson and by 35.3% during the second quarter. Janney Montgomery Scott LLC now owns 43,293 shares of the medical instruments supplier’s stock worth $8,447,000 after acquiring an additional 11,300 shares during the period. Bessemer Group Inc. raised its stake in Becton, Dickinson and by 1.4% in the 2nd quarter. Bessemer Group Inc. now owns 978,050 shares of the medical instruments supplier’s stock worth $190,827,000 after purchasing an additional 13,263 shares in the last quarter. Pictet Asset Management Ltd. raised its stake in Becton, Dickinson and by 9.3% in the 2nd quarter. Pictet Asset Management Ltd. now owns 246,404 shares of the medical instruments supplier’s stock worth $46,627,000 after purchasing an additional 21,022 shares in the last quarter. Union Bankshares Corp raised its stake in Becton, Dickinson and by 1.7% in the 2nd quarter. Union Bankshares Corp now owns 22,335 shares of the medical instruments supplier’s stock worth $4,357,000 after purchasing an additional 381 shares in the last quarter. Finally, State of Alaska Department of Revenue raised its stake in Becton, Dickinson and by 5.8% in the 2nd quarter. State of Alaska Department of Revenue now owns 32,999 shares of the medical instruments supplier’s stock worth $6,438,000 after purchasing an additional 1,819 shares in the last quarter. 87.12% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.watchlistnews.com/northwestern-mutual-investment-management-company-llc-decreases-stake-in-becton-dickinson-and-company-bdx/1604598.html.

In related news, insider Gary M. Cohen sold 15,512 shares of the business’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the transaction, the insider now directly owns 95,781 shares in the company, valued at $19,517,294.37. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the business’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total value of $1,178,735.11. Following the transaction, the insider now owns 12,861 shares of the company’s stock, valued at $2,538,890.01. The disclosure for this sale can be found here. Insiders sold a total of 75,904 shares of company stock worth $15,242,688 over the last quarter. Corporate insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company (NYSE:BDX) opened at 196.29 on Tuesday. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63. The stock has a 50 day moving average price of $197.79 and a 200 day moving average price of $192.22. The company has a market cap of $44.67 billion, a price-to-earnings ratio of 56.85 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating the consensus estimate of $2.44 by $0.02. The company had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. Becton, Dickinson and’s revenue for the quarter was down 5.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.35 earnings per share. On average, equities analysts forecast that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 29th. Shareholders of record on Friday, September 8th were paid a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 1.49%. The ex-dividend date was Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

A number of analysts have issued reports on the stock. Raymond James Financial, Inc. raised shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and cut their price objective for the company from $210.00 to $180.00 in a report on Friday, June 30th. Cowen and Company reaffirmed an “outperform” rating and set a $230.00 target price (up from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. BidaskClub raised shares of Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 target price on the stock in a report on Monday, July 17th. Finally, Bank of America Corporation reiterated a “buy” rating and issued a $225.00 price target (up from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Five equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $200.93.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.